LeMaitre Vascular (NASDAQ:LMAT) Cut to Hold at StockNews.com

StockNews.com downgraded shares of LeMaitre Vascular (NASDAQ:LMAT) from a buy rating to a hold rating in a research report sent to investors on Friday.

A number of other equities analysts have also weighed in on LMAT. Cantor Fitzgerald began coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 target price on the stock. Barrington Research upped their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. JMP Securities lifted their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Finally, Oppenheimer reissued an “outperform” rating and issued a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $94.57.

LeMaitre Vascular Trading Up 0.4 %

Shares of LeMaitre Vascular stock opened at $100.69 on Friday. The company’s 50-day moving average price is $97.65 and its 200-day moving average price is $89.54. LeMaitre Vascular has a 12-month low of $52.88 and a 12-month high of $109.58. The company has a market cap of $2.26 billion, a price-to-earnings ratio of 55.02, a PEG ratio of 2.47 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. The business had revenue of $54.82 million for the quarter, compared to analysts’ expectations of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business’s revenue for the quarter was up 15.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.33 EPS. On average, sell-side analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Investors of record on Thursday, November 21st were issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.64%. The ex-dividend date of this dividend was Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is currently 34.97%.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at $231,148.66. The trade was a 62.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 10.79% of the stock is currently owned by insiders.

Institutional Trading of LeMaitre Vascular

Institutional investors have recently made changes to their positions in the stock. NBC Securities Inc. raised its holdings in LeMaitre Vascular by 73.2% during the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 183 shares during the last quarter. West Oak Capital LLC purchased a new position in shares of LeMaitre Vascular in the second quarter valued at about $58,000. USA Financial Formulas bought a new position in shares of LeMaitre Vascular during the third quarter valued at about $60,000. nVerses Capital LLC boosted its holdings in shares of LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after purchasing an additional 200 shares during the period. Finally, GAMMA Investing LLC grew its stake in shares of LeMaitre Vascular by 34.3% in the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 188 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.